Exploring the RANK–RANKL–OPG axis in MASLD enhances our understanding of the disease and opens up promising avenues for therapeutic interventions across hepatology, endocrinology, and bone metabolism. Here, TNFSF11 is linked to metabolic dysfunction-associated steatotic liver disease.